EA201700456A1 - Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf - Google Patents
Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegfInfo
- Publication number
- EA201700456A1 EA201700456A1 EA201700456A EA201700456A EA201700456A1 EA 201700456 A1 EA201700456 A1 EA 201700456A1 EA 201700456 A EA201700456 A EA 201700456A EA 201700456 A EA201700456 A EA 201700456A EA 201700456 A1 EA201700456 A1 EA 201700456A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pharmaceutical composition
- nucleotide sequence
- volf
- transgene
- basis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Выявлены точечные изменения нуклеотидной последовательности 3'UTR гена vegf, которые существенно увеличивают время жизни продукта его транскрипции - мРНК в клетках млекопитающих. Экспериментальным путем выбрана генная конструкция с оптимальным перечнем выявленных мутаций, характеризующаяся наибольшим временем жизни мРНК. Подтвержден биологический эффект разработанной генной конструкции и фармацевтической композиции на ее основе in vitro и in vivo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2015119768A RU2612497C2 (ru) | 2015-05-26 | 2015-05-26 | Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf |
PCT/RU2015/000852 WO2016190774A1 (ru) | 2015-05-26 | 2015-12-07 | Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201700456A1 true EA201700456A1 (ru) | 2018-06-29 |
EA039395B1 EA039395B1 (ru) | 2022-01-21 |
Family
ID=57392933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201700456A EA039395B1 (ru) | 2015-05-26 | 2015-12-07 | СПОСОБ ПОЛУЧЕНИЯ ГЕННОЙ КОНСТРУКЦИИ И ПЛАЗМИДНАЯ ДНК С УВЕЛИЧЕННЫМ ВРЕМЕНЕМ ЖИЗНИ мРНК ТРАНСГЕНА VEGF В КЛЕТКЕ МЛЕКОПИТАЮЩЕГО, ПЛАЗМИДНАЯ ДНК ГЕНА VEGF165, мРНК, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ПЛАЗМИДНОЙ ДНК |
Country Status (10)
Country | Link |
---|---|
US (2) | US9896493B2 (ru) |
EP (1) | EP3305901B1 (ru) |
CN (1) | CN107614687B (ru) |
AU (1) | AU2015396177B2 (ru) |
BR (1) | BR112017023058B1 (ru) |
CA (1) | CA2985608C (ru) |
EA (1) | EA039395B1 (ru) |
MX (1) | MX2017013206A (ru) |
RU (1) | RU2612497C2 (ru) |
WO (1) | WO2016190774A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114908089B (zh) * | 2021-02-08 | 2024-03-15 | 上海细胞治疗集团有限公司 | 3’utr的构建方法和应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
US5587300A (en) * | 1994-04-26 | 1996-12-24 | Wisconsin Ulumni Research Foundation | Method to increase regulatory molecule production |
US6613563B1 (en) | 1997-03-14 | 2003-09-02 | Selective Gentics, Inc. | Viral vectors with modified tropism |
US6627436B2 (en) | 1997-10-31 | 2003-09-30 | Stratagene | Vector for gene expression in prokaryotic and eukaryotic systems |
CA2322232A1 (en) | 1998-03-13 | 1999-09-16 | American Home Products Corporation | Lyophilized polynucleotide composition, method of preparation, and uses thereof |
US7598079B2 (en) * | 1998-12-24 | 2009-10-06 | Novation Pharmaceuticals, Inc. | Assay for identifying compounds which affect stability of mRNA |
WO2000047235A2 (en) | 1999-02-10 | 2000-08-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of stimulating angiogenesis |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US7288521B2 (en) | 2000-04-06 | 2007-10-30 | Franco Wayne P | Growth factor therapy mobilization of stem cells into the peripheral blood |
CN1351055A (zh) | 2000-10-26 | 2002-05-29 | 上海博德基因开发有限公司 | 一种新的多肽——人的血管内皮生长因子165受体(vegf-165r)10.67和编码这种多肽的多核苷酸 |
CA2451311A1 (en) * | 2001-06-20 | 2003-01-03 | Ludwig Institute For Cancer Research | Stimulation of vascularization with vegf-b |
US7981863B2 (en) | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
CN100431611C (zh) | 2002-07-04 | 2008-11-12 | 朱静亚 | 多肽-脂质体与人血管内皮生长因子基因重组质粒复合物及用途 |
ATE474604T1 (de) | 2002-12-02 | 2010-08-15 | Anges Mg Inc | Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen |
JP2008512997A (ja) | 2004-09-17 | 2008-05-01 | サントリオン | プラスミドdnaの安定な液体製剤 |
RU2297848C2 (ru) | 2005-05-11 | 2007-04-27 | Александр Веньяминович Иткес | Генно-инженерная конструкция vegf-ибмед (vegf-ibmed) |
ES2338400B1 (es) | 2008-05-06 | 2011-09-14 | David Benet Ferrus | Conjunto de moleculas antiangiogenicas y su uso. |
CA2753362C (en) | 2009-02-24 | 2018-06-19 | The Scripps Research Institute | Reengineering mrna primary structure for enhanced protein production |
US8367350B2 (en) | 2009-04-29 | 2013-02-05 | Morehouse School Of Medicine | Compositions and methods for diagnosis, prognosis and management of malaria |
RU2431669C2 (ru) * | 2009-06-23 | 2011-10-20 | Государственное образовательное учреждение высшего профессионального образования "Казанский государственный университет им. В.И. Ульянова-Ленина" | Способ получения лекарственного препарата генетически модифицированных клеток |
RU2542385C2 (ru) * | 2012-08-31 | 2015-02-20 | Общество с ограниченной ответственностью "НекстГен" | Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека |
-
2015
- 2015-05-26 RU RU2015119768A patent/RU2612497C2/ru active
- 2015-12-07 MX MX2017013206A patent/MX2017013206A/es unknown
- 2015-12-07 EA EA201700456A patent/EA039395B1/ru unknown
- 2015-12-07 CA CA2985608A patent/CA2985608C/en active Active
- 2015-12-07 CN CN201580080399.1A patent/CN107614687B/zh active Active
- 2015-12-07 EP EP15893474.5A patent/EP3305901B1/en active Active
- 2015-12-07 WO PCT/RU2015/000852 patent/WO2016190774A1/ru active Application Filing
- 2015-12-07 BR BR112017023058-5A patent/BR112017023058B1/pt active IP Right Grant
- 2015-12-07 AU AU2015396177A patent/AU2015396177B2/en active Active
-
2016
- 2016-03-15 US US15/070,239 patent/US9896493B2/en active Active
-
2017
- 2017-11-21 US US15/819,157 patent/US10040837B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20160347803A1 (en) | 2016-12-01 |
US9896493B2 (en) | 2018-02-20 |
EP3305901A4 (en) | 2018-10-24 |
US20180086800A1 (en) | 2018-03-29 |
RU2015119768A (ru) | 2016-12-20 |
RU2612497C2 (ru) | 2017-03-09 |
BR112017023058A2 (pt) | 2018-10-16 |
AU2015396177B2 (en) | 2019-02-28 |
WO2016190774A1 (ru) | 2016-12-01 |
MX2017013206A (es) | 2018-02-15 |
EP3305901B1 (en) | 2020-09-30 |
EP3305901A1 (en) | 2018-04-11 |
CN107614687B (zh) | 2021-05-28 |
US10040837B2 (en) | 2018-08-07 |
CA2985608A1 (en) | 2016-12-01 |
CN107614687A (zh) | 2018-01-19 |
BR112017023058B1 (pt) | 2024-03-05 |
AU2015396177A1 (en) | 2017-11-02 |
CA2985608C (en) | 2021-06-15 |
EA039395B1 (ru) | 2022-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020003995A (es) | Nuevas moleculas de acido nucleico artificiales. | |
EA201991369A1 (ru) | Модифицированные направляющие рнк | |
BR112016025519A2 (pt) | engenharia genética in vivo com vetores de adenovírus | |
EP3728596A4 (en) | CONSTRUCTION OF NUCLEIC ACID ALLOWING THE EXPRESSION OF A GENE IN VITRO AND IN VIVO | |
CL2019003842A1 (es) | Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas. | |
CY1124327T1 (el) | Τροποποιηση της εκφρασης του ιου ηπατιτιδας β (hbv) | |
EA202191313A1 (ru) | Композиции на основе липидных наночастиц | |
EA201790698A1 (ru) | Новые сайты интеграции cho и их применения | |
ECSP19017082A (es) | Regulación de la expresión génica usando nucleasas modificadas | |
MX2022006652A (es) | Proteinas de capside modificadas para un suministro mejorado de vectores de parvovirus. | |
EA201692318A1 (ru) | Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина | |
CY1120103T1 (el) | Κλιμακωσιμο συστημα παραγωγης λεντιικου φορεα, συμβατο με βιομηχανικες φαρμακευτικες εφαρμογες | |
MX2021008143A (es) | Metodos para cosechar cultivos de celulas de mamifero. | |
MX2020006065A (es) | Metodos y productos para la produccion y administracion de acido nucleico. | |
EP4241784A3 (en) | Artificial nucleic acid molecules for improved protein expression | |
EA201790789A1 (ru) | Композиции и способы, предназначенные для ингибирования экспрессии гена hao1 (оксидазы 1 гидроксикислот (гликолат-оксидазы)) | |
MX346923B (es) | Genes y proteinas para sintesis de alcanoil-coa. | |
MX357803B (es) | Moléculas de ácido nucleico artificiales. | |
CY1123119T1 (el) | Αντινοηματικο νουκλεϊκο οξυ | |
BRPI0819526B8 (pt) | Sequência de ácido nucleico de precursor de mirna artificial, construção recombinante e método para reduzir a expressão de uma sequência alvo | |
BR112013007862A2 (pt) | ácidos nucleicos manipulados e métodos de uso dos mesmos. | |
MX358706B (es) | Moleculas de acido nucleico artificiales que comprenden un top 5´utr. | |
UY34227A (es) | Acido nucleico recombinante que codifica el gen de la toxina axmi270, vectores, células, plantas y sus métodos de empleo | |
EA201892588A1 (ru) | Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации | |
WO2013119371A3 (en) | Mini-intronic plasmid vectors |